Alvotech (STO:ALVO.SDB)

Market Cap	14.38B -66.4%
Revenue (ttm)	5.40B +45.6%
Net Income	654.88M
EPS	2.26
Shares Out	n/a
PE Ratio	21.95
Forward PE	23.44
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,979
Average Volume	12,415
Open	44.14
Previous Close	44.14
Day's Range	43.50 - 45.61
52-Week Range	40.89 - 157.00
Beta	0.13
RSI	36.94
Earnings Date	Mar 18, 2026

About Alvotech

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company’s lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory cond...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2013
• Employees: 1,012
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: ALVO.SDB

Financial Performance

In 2024, Alvotech's revenue was $491.98 million, an increase of 426.84% compared to the previous year's $93.38 million. Losses were -$231.86 million, -57.98% less than in 2023.

Financial numbers in USD